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Abstract 
The interest in using physiologically-based pharmacokinetic (PBPK) models as a support to the drug 
development decision making process has rapidly increased in the last years. These kind of models are 
examples of the “bottom up” modelling strategy, which progressively integrates into a mechanistic 
framework different information as soon as they become available along the drug development. For this 
reason PBPK models can be used with different aims, from the early stages of drug development up to the 
clinical phases. Different software tools are nowadays available. They can be categorized in “designed 
software” and “open software”. The first ones typically include commercial platforms expressly designed to 
implement PBPK models, in which the model structure is pre-defined, assumptions are generally not 
explicitly declared and equations are hidden to the user. Even if the software is validated and routinely used 
in the pharmaceutical industry, sometimes they do not allow working with the flexibility needed to cope 
with specific applications/tasks. For this reason, some scientists prefer to define and implement their own 
PBPK tool in “open” software. This paper shows how to build an in-house PBPK tool from species-related 
physiological information available in the literature and a limited number of drug specific parameters 
generally made available by the drug development process. It also reports the results of an evaluation 
exercise that compares simulated plasma concentration-time profiles and related pharmacokinetic (PK) 
parameters (i.e., AUC, Cmax and Tmax) with literature and in-house data. This evaluation involved 25 drugs 
with different physico-chemical properties, intravenously or orally administrated in three different species 
(i.e., rat, dog and man). The comparison shows that model predictions have a good degree of accuracy, 
since the average fold error for all the considered PK parameters is close to 1 and only in few cases the fold 
error is greater than 2. In summary, the paper demonstrates that addressing specific aims when needed is 
possible by creation of in-house PBPK tools with satisfactory performances and it provides some 
suggestions how to do that. 
 Keywords 
Model Based Drug Development; PBPK models; Oral administration; Pharmacokinetics; Model-based 
prediction; In Vitro In Vivo Extrapolation 
 
Introduction 
Drug development is an extremely long and expensive process. Pharmaceutical companies look for 
methodologies able to reduce the attrition rate and to speed-up the whole process. The in silico study of 
the pharmacokinetics (PK) through modelling and simulation (M&S) can help on this and, in the last 
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decades, received attention of both industries and regulatory authorities [1,2]. One of the possible 
strategies that allows the in silico study of ADMET is the use of physiologically-based pharmacokinetic 
(PBPK) models. 
In PBPK models the living organism is described as a set of compartments representing organs and 
tissues connected by the blood circulation. Hence, differently from the compartmental modelling approach, 
in PBPK models there is a direct correspondence between anatomical structures and model compartments. 
The time course of the drug concentration in each compartment is described through a mass-balance 
equation [3]. Specific reactions if needed and known can be easily added in the different compartments, 
providing a more detailed mechanistic description. One of the most interesting characteristics of PBPK 
models is that, as in systems pharmacology, model parameters can be divided into system-specific (e.g., 
organ volumes and blood fluxes) and compound-related (e.g., solubility, permeability, tissue binding). This 
means that it is possible to create pre-built drug-independent model structures that can be re-used for 
predicting the exposure to different compounds or to xenobiotics in species different from those for which 
the model was originally developed [3,4]. In fact, one of the first and more extensive field of PBPK 
modelling approach application was the preclinical to clinical translation in toxicology, where for ethical 
reasons, the exposure of humans to pollutants or toxic agents is not allowed and then it is only possible to 
predict the human exposure on the basis of preclinical data [5].  
In the literature, examples of application and assessment of PBPK models of different complexity are 
reported along the whole drug development process. Different type of information can be integrated from 
the beginning in the PBPK mechanistic framework and gradually added, updated and refined as they are 
made available by the in vitro/in vivo studies. Therefore, PBPK modelling approach represents a good 
example of incremental strategy to the model building.  
One possible application of PBPK models in early stages of drug development is to prioritize candidates 
before performing in vivo experiments. The cost to generate in vivo data is in fact higher than that to 
characterize candidates in vitro (e.g., their main properties can be routinely determined via high-
throughput techniques). The in vitro candidate properties can hence be combined with physiological 
species-specific information to predict the in vivo PK in the preclinical species of interest [6-8]. Once 
preclinical in vivo data become available for the selected candidate, the simulated profiles can be compared 
with experimental data to verify if some of the model assumptions were violated. If this is the case, the 
model can be refined following the “learn, confirm and refine” paradigm. The adjusted model can be 
further used and expanded, for example, for predicting other routes of administration (e.g., oral - PO - after 
intravenous - IV) in the same species or the same route in other species. For example, PBPK models can be 
used to extrapolate PK from animals to man (e.g., healthy volunteers), by updating the species-specific 
model parameters and collecting additional compound-related in vitro data [8,9]. Furthermore, within the 
clinical development context, PBPK models can be used to extrapolate PK from healthy volunteers to 
patients or can be used to predict PK in special populations, like children and elderly, integrating into the 
model the physiological-related changes due to the specific physiological or pathological condition [2].  
In recent years, the number of PBPK model publications and regulatory submissions has grown rapidly 
and the regulatory agencies are working to define the best practice on development, qualification, 
application and reporting of PBPK modelling activities [10]. In 2016, EMA published a draft version of a 
guideline about that and, in 2018, FDA provided guidelines about PBPK analysis formats and contents of 
applications [11,12]. Furthermore, a number of drug labels are informed by the results of PBPK model 
simulations as documented by Jamei [4]. This huge increase in the use of PBPK models has been made 
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possible by factors such as the increased computational power necessary to handle mathematical 
complexity, the improvement in biological systems understanding and the advancing in drug property 
predictions from in vitro and in silico data [4,8].  
Nowadays, scientists have in their hands two kind of tools for working with PBPK models: the 
“designed” software and the “open” software [1]. The first group refers mainly to commercial software 
platforms, in which generally the PBPK model structure is pre-defined, assumptions are not completely 
made explicit and equations are generally hidden to the user. They also include often ready to use 
databases of parameter values and population libraries that allow, for example, simulation of PK profiles in 
different conditions and for different demographics. Examples of such software are GastroPlus™ 
(Simulation Plus Inc.), PK-sim (Bayer Technologies Services), Simcyp Simulator™ (Certara). The second group 
refers to software not specifically designed to work with PBPK models, but originally developed for 
engineers, mathematicians and statisticians, in which the user needs to write the code with the equations 
to implement the model from scratch. Examples of “open” software are MATLAB (The Mathworks Inc.), R 
(R Development Core Team), Berkeley-Madonna (University of California), SAAM II (University of 
Washington). 
 “Designed” software helped the diffusion of PBPK models for their intrinsic advantages such as the 
presence of user-friendly interfaces, the fact that the user does not need to have expertise in programming 
languages, the specific scientific-technical support by software vendors and, mainly, the huge amount of 
knowledge encoded in these tools. For the same reasons, the main risk in using these software tools is that, 
if the user has not sufficient awareness about the model assumptions and the parameter relationships, the 
results can be misinterpreted and due to the high complexity of the encoded models can be very difficult to 
understand which parameters or processes are responsible of possible poor predictions. With the “open 
software” the model is directly implemented by the user, hence, a deep understanding of the model 
assumptions, interdisciplinary skills ranging from physiology to programming and enough modelling 
expertise are needed. Model parameter values have to be found somewhere directly by the modeller. This 
is not an easy task and necessarily leads to build simpler models, but perfectly adequate to address at least 
some of the questions. One advantage of an open model structure is that it can be personalized to cope 
with specific problems such as the study of a particular route of administration or the study of the 
pharmacodynamics (PD), through a PBPK-PD model [1]. Not only the academia but also companies are 
using open software for PBPK modelling. Some of them use in-house developed tools, tailored on specific 
needs, to assist their drug development process [13]. 
Basic PBPK models for IV administrations can be built from literature information. Then, they can be 
extended by integrating other routes of administration to study, for example gastrointestinal absorption 
(examples implemented in open software are reported in [13]) or special routes such as pulmonary [14] or 
vaginal delivery [15], or more generally, by integrating specific ADME processes. In this work, through an 
example, it is shown how this process can be actually done. A basic PBPK model for IV administrations in 
different species (rat, dog, man) is built and then extended to PO administrations. To help the reader, all 
the relevant knowledge collected form the literature, such as parameter values or mathematical 
relationships, is summarized in the Supplementary material. The proposed model has been implemented in 
MATLAB and evaluated simulating IV and PO administration experiments in three species (rat, dog, man) 
for different compounds and comparing simulated profiles with published and in-house data.  
Figure 1 summarizes the key points of the workflow suggested in the paper and presented in detail in 
the next sections, related to model building, model evaluation and model customization to cope with 
specific case studies.  
ADMET & DMPK 7(1) (2019) 4-21 Building in-house PBPK modelling tools 
doi: 10.5599/admet.638 7 
 
Figure 1. A schematic representation of the proposed workflow for model building, evaluation and 
application. 
Model building 
Model structure: the compartments 
PBPK models consist of a series of compartments representing the body organs/tissues. Those typically 
included in a basic PBPK model are: adipose, brain, gut, heart, kidneys, lung, muscle, skin and spleen 
[3,7,16]. Depending on the specific needs, other tissues can be included or lumped together. Fig. 2 shows 
the basic structure adopted in this work. 
 
Figure 2. A basic IV PBPK model structure extended with a gastrointestinal absorption model. 
The drug concentration CT in the generic tissue T is governed by the following mass balance differential 
equation: 
dCT/dt = 1/VT(QTCin – QTCT/PT:B-CLTCin) (1) 
where VT and QT are the tissue volume and blood flux, respectively; Cin is the blood drug concentration in 
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input to the tissue, that is the arterial blood concentration for all the tissues except for the lung which 
receives the venous blood; PT:B is the tissue to blood partition coefficient; CLT is the tissue clearance, 
present in some of the tissues [7]. 
The equation for the venous compartment, receiving as input the output of all the other tissues (except 
lung) has the following expression: 
dCVEN/dt = 1/VVEN (∑QTCT/PT:B -QVENCVEN +DIV) (2) 
where CVEN, VVEN and QVEN are the venous drug concentration, volume and flux, respectively, and DIV 
represents the IV dose, if present. The mass balance equation for the arterial compartment can be 
analogously derived as: 
dCART/dt = 1/VART (QLUNGCLUNG/PLUNG:B -QARTCART) (3) 
where CART, VART and QART are the arterial drug concentration, volume and flux, respectively. Fluxes QVEN, QART 
and QLUNG are equal to the cardiac output. 
Each tissue could be modelled as perfusion-limited or permeability-limited. The first situation generally 
occurs for small lipophilic compounds for which the tissue perfusion is the step limiting the absorption and 
it is described through the Eq. (1). Instead, the second situation generally occurs for large hydrophilic 
compounds for which the permeation through the cell membrane is the limiting step. To model that, the 
tissue compartment can be divided in two parts: the extravascular space and the vascular space, divided by 
a membrane which acts as a barrier [3]. Then, typical equations of a permeability-limited tissue (without 
clearance) can be the following ones: 
dCT,VASC/dt = (1/VT,VASC)((QTCin -QTCT,VASC)-PS CT,VASC fuB+PS CT,EV fuT) 
dCT,EV/dt = (1/VT,EV) (PS CT,VASCfuB-PS CT,EVfuT) 
(4) 
(5) 
where CT,VASC is the drug concentration in the vascular part of the tissue T and VT,VASC its volume; CT,EV and 
VT,EV are the corresponding quantities for the extravascular part of the tissue; PS is the permeability-surface 
product which takes into account the limitation of the permeability that prevents a fast distribution of the 
drug into the tissue; fuB and fuT are the unbounded drug fraction in blood and tissue, respectively [17]. They 
can be computed as fuB= fuP/BP and fuT= fuB/PT:B, where fuP is the unbounded drug fraction in plasma and BP 
is blood to plasma ratio.  
To describe PO administrations, a model of gastrointestinal absorption has to be added to the basic 
structure just described, which is able to predict tissue drug concentrations only after an IV administration. 
In this paper, a simplified version of the advanced compartmental absorption and transit (ACAT) model was 
adopted [18]. The gastrointestinal system was divided in 9 compartments, the first, receiving the solid drug, 
is the stomach, the other segments represent the small intestine and the last compartment the colon. Each 
intestinal section is composed by a compartment in which the drug is in its undissolved form (from here it 
can dissolve or transit in the same form in the subsequent section) and by a compartment in which the 
drug is dissolved in the physiological fluids (from there drug can be absorbed or transit in the subsequent 
section; in colon drug can also be excreted). Two detailed examples of PBPK models in which the 
gastrointestinal absorption modelling is based on the ACAT model can be found in [16,19]. 
As discussed in the introduction, in PBPK models it is possible to distinguish from system-specific and 
compound-related parameters. In the next subsections, it will be discussed which are the parameters that 
can be found in the literature and which, instead, need to be derived from in vitro experiments through in 
vitro-in vivo extrapolation techniques [20].  
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System-specific parameters 
System-specific parameters, such as blood fluxes and volumes, can be found in the literature; some of 
the sources frequently used in PBPK modelling are [21,22], in which values are reported for different 
species. Values used to build the here proposed PBPK model were taken for all the tissues from them. The 
volume of blood was taken from [22]. It was divided in arterial and venous blood following [22], in which a 
75 % vs 25 % was suggested for arterial and venous blood volume, respectively. The volume of the rest of 
the body compartment was calculated assuming that all the tissues included in the model represent the 
85 % of the total body weight (BW) [23]. Hence, its weight is calculated subtracting the sum of the weights 
of all the other compartments from the 85 % of BW. 
The volumes of the extravascular and vascular compartments for the tissues with a permeability-limited 
kinetics can be calculated from the fractions of vascular and interstitial spaces, that can be found for rats in 
[24]. In the model here proposed, the vascular compartment includes also the interstitial space. For other 
species, it was assumed that that the ratio between extravascular and vascular volumes is the same as in 
rats [25]. Organ surfaces needed to compute the permeability-surface product (PS) for permeability limited 
organs (muscle and rest of the body in model of Figure 2) according to the authors’ knowledge are not 
present in the literature, except for lung for which volumes and surfaces for the tracheobronchial and 
alveolar regions are available [4]. Hence, in this work, organ surfaces for other tissues were obtained by 
scaling the surface area from the tracheobronchial region through the following formula: 
where ST and VT,EV are the surface and the extravascular volume of the tissue of interest, respectively; 
analogously, STB and VTB,EV are the tracheobronchial surface and extravascular volume, respectively.  
For what concerns the parametrization of the gastrointestinal absorption model, lumen volumes of the 
different intestinal segments and the relative pH values were obtained from [25] for rat, dog and man. The 
transit constants Kt can be calculated from the mean residence time (MRT) as 1/MRT. MRTs of small 
intestine segments can be obtained dividing the total small intestine MRT reported in the literature by 7 
(assuming, hence, that the transit time is the same for each segment). MRT values are summarized in 
Table 1 with the respective sources. Intestinal radius values for all the species can be found in [25]. 
Table 1 - Values of the intestinal MRT for three species with references. 





Values reported in the literature show a 
certain variability, ranging from 2.7 min in 
[16] to 60 min in [26]. 
88 min [22] 228 min [25] 
Dog 
Values reported in the literature show a 
certain variability, ranging from 12.5 min in 
[16] to 96 min in [22]. 
109 min [22] 
9.4 h, obtained by subtracting 
from the total gut transit time 
the stomach and the small 
intestine ones [22]. 
Man 
Values reported in the literature show a 
certain variability, ranging from 15 min in [16] 
to 78 min in [22]. 
199.2 min [27] 11-92 h [25] 
 
All the parameters values discussed in this section are reported for the three considered species in the 
Supplementary Material (System-specific parameter values section). 
ST = STB(VT,EV/VTB,EV)
0.67 (6) 
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 Compound-related parameters 
In case of PO drug delivery, before the drug is absorbed, it undergoes to the dissolution process. The 
dissolution process depends on the physico-chemical characteristics of the compound and on the 
dissolution medium. One of the widely used equations to model the dissolution process is the Nernst-
Brunner equation [28,29], reported below under the hypothesis that particles are spherical:  
where kd is the dissolution rate, T is the diffusion layer thickness, Cs the solubility of the drug in the 
dissolving medium, r, ρ and D are the particle radius, density and diffusivity, respectively. The diffusion 
layer thickness can be computed following the approximation of Hintz and Johnson [30]: 
T = r if r < 30 µm 
T = 30 µm, otherwise 
(8) 
The diffusivity can be calculated through the Stokes-Einstein equation: 
D = (kBT)/(6πηRs ) (9) 
where kB is the Boltzmann constant, T is the absolute temperature in Kelvin, η is the solute viscosity
1 















where MW is the molecular weight, NA is the Avogadro Number, ρ is the drug density (in kg∙m
-1). 
Drug solubility is pH dependent except for non-ionizing compounds and it changes along the gut due to 
changes in the physiological pH. This can be taken into account by expressing solubilities at different pH 
values through the Henderson-Hasselbalch equations [32]. It depends on the specific nature of the 








 where CspH is the solubility at a certain pH; pKa is the acidic dissociation constant of the solute; Sint is the 
intrinsic solubility. For the other compound natures, relationships are reported in the Supplementary 
Material (Compound-related parameter relationships section). 
Absorption 
The absorption rate constants of the gastrointestinal absorption model, ka, were calculated starting 
from the measurement of the apparent permeability, obtained from the in vitro Caco2 cell test. In 
particular from [33], ka can be expressed as Peff2/R, where Peff is the effective permeability and R is the 
intestinal radius. The value of human effective permeability, can be calculated following [34] as:  
log Peff,human = 0.4926 log Papp - 0.1454     (13) 
where Papp is the Caco2 apparent permeability measured at pH 7.4 and expressed in 10
-6 cm/s. The resulting 
                                                     
 
1
 In this work, the solute viscosity has been fixed to the water viscosity at 37 °C, i.e. 0.69 mPa s. 
kd = (3D/(ρrT))(Cs-C) (7) 
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value of Peff,human is expressed in 10
-4 cm/s. Other relationships are present in [29] for PAMPA and MDCK 
assays. The effective permeability in rats, Peff,rat, can be obtained by the following relationship [34]: 
Peff,rat = (Peff,human - 0.03)/3.6 (14) 
For dogs, in this work, it was assumed that Peff,dog = Peff,human, because no specific information were found 
in the literature. 
Distribution 
The compound-related parameters characterizing the drug distribution process are PT:B, defined as the 
ratio between the total drug concentration of a compound in a tissue T and the total drug blood 
concentration at the steady state. While in the past the values of these parameters originated from 
expensive and time-consuming experiments, nowadays they can be calculated by in silico models 
accounting for the tissue composition in terms of of water, lipids, and proteins. The two most widely used 
methods are the one developed by Poulin and co-workers [35,36] and the one proposed by Rodgers and 
co-workers, which extends the first one to take into account the nature of the compound (e.g., acid, base) 
and ionization phenomenon [37,38]. These models are reported for the reader in the Supplementary 
Material (Compound-related parameter relationships section). 
Metabolism and Elimination 
The organs that generally constitute the major route of elimination in the organism are the liver and the 
gut, responsible for the first pass effect, and the kidneys.  
Hepatic metabolic clearance can be obtained through the in vitro - in vivo extrapolation. It consists of 
three steps [39]: i) determination of in vitro intrinsic clearance CLint (that can be obtained from hepatocytes, 
microsomes or recombinant enzymes); ii) scaling of CLint to an in vivo value, here indicated as CLint,vivo, by 
using appropriate scaling factor to obtain the value for the whole liver; iii) conversion of CLint,vivo to a net 
value of hepatic clearance CLH. The scaling factor of step 2 is, in case of test with microsomes, the milligram 
of proteins per gram of liver (MPPGL) and, in case of hepatocytes, is the millions of hepatocytes per gram of 
liver (HPGL). Of course, these factors have to be multiplied for the liver weight to obtain the final value for 
the whole liver. The different values for rat, dog and man are reported in the Supplementary Material. One 
of the widely used models in step 3 to obtain CLH is the well-stirred liver model [40], here reported: 
CLH =((CLint, vivo)(fuP/fuH)QLIVER)/(CLint,vivo(fuP/fuH)+ QLIVER) (15) 
where QLIVER is the liver blood flow and fuH is the fraction unbound in microsomes or hepatocytes. If fuH is 
not known, it can be assumed that is equal to 1 (binding negligible) or that fuH = fuP (the liver binding is 
equivalent to plasma protein binding) [7]. From CLH, the hepatic extraction ratio EH can then be calculated 
as: 
 and then the resulting liver mass balance differential equation can be expressed as [32]: 
The intestinal contribution to the first pass metabolism can be obtained, in case of CYP metabolized 
drugs, by the “Qgut” model [34] as reported in the Supplementary Material. The equation describing the 
variation of the drug concentration in the gut can be expressed as follows [16]: 
EH = CLH/QLiver (16) 
dCLIVER/dt = 1/VLIVER{[(QLIVER-QGUT - QSPLEEN)CART + QGUTCGUT/PGUT:B + QSPLEENCSPLEEN/PSPLEEN:B -   
- QLIVERCLIVER/PLIVER:B ]-[(QLIVER-QGUT -QSPLEEN)CART+QGUTCGUT/PGUT:B + QSPLEENCSPLEEN/PSPLEEN:B ]EH} 
(17) 
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dCGUT/dt = 1/VGUT((QGUTCART-QGUTCGUT/PGUT:B) + FGUT (∑ka ai,diss)),  (18) 
where QGUT and VGUT are the gut blood flux and volume, respectively; PGUT:B is the gut to blood partition 
coefficient; FGUT is the fraction of drug that reaches gut escaping the intestinal first pass metabolism; ai,diss is 
the amount of dissolved drug for the i-th compartment of the gastrointestinal absorption model. 
The renal clearance can be calculated, in the simplest form neglecting processes of active secretion and 
tubular reabsorption, as GFR∙fuB [25], where GFR is the glomerular filtration rate. The resulting equation for 
the kidney compartment is: 
Results and discussion 
Model evaluation 
The PBPK model here presented was evaluated on IV and PO administrations by comparing model 
predictions with experimental data coming from the literature or in-house experiments, involving different 
drugs/compounds, administered in single dose or multiple doses, in three different species (i.e., rat, dog 
and man). Studies were selected to explore drugs with different physico-chemical properties and on the 
basis of the availability of all the drug parameters required to perform the simulations, summarized in Table 
2.  
Table 2 - Drug specific information required to use the proposed PBPK model 
Parameter Symbol Notes 
Nature of the compound  e.g. acid, base, neutral, zwitterion 
Acidic dissociation constant pKa e.g. obtained by in silico predictions 




Rarely available, a value frequently present in the 
literature is that used as default in the 
GastroPlus™ software [16,41,42], i.e. 1 g/ml. 
Particle radius r 
If not available, a value suggested in the literature 
is that used as default in the GastroPlus™ 
software [43], i.e. 25 µm. 
Intrinsic solubility Cs 
If not available, but the solubility is known to a 
certain pH, Cs can be calculated with the 
Henderson-Hasselbalch equations. 
In vitro apparent permeability Papp e.g. obtained from Caco2 or PAMPA test 
In vitro intrinsic clearance CLint 
e.g. obtained in vitro from microsomes or 
hepatocytes  
Blood to plasma ratio BP e.g. obtained from in vitro test 
Fraction unbound in plasma fuP e.g. obtained from in vitro test 
Log of n-octanol:water partition 
coefficient 
log P 
e.g. obtained from in vitro test or in silico 
calculated 
Log of distribution coefficient (at a 
specified pH) 
log DpH 
e.g. obtained from in vitro test or in silico 
calculated 
The final list of selected compounds with the references in which experimental data and drug 
parameters were found is reported in Table 3.  
dCKIDNEY/dt = 1/VKIDNEY(QKIDNEY(CART-CKIDNEY/PKIDNEY:B))-GFR fub CART) (19) 
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Table 3. Compounds used for the evaluation of the proposed PBPK model with references in 
which the data and/or parameter values were taken from 
Drug/Compound Drug Parameters References Study References 
Amitriptyline [44], [45], [46] [45] 
R-Carvedilol [47] [47] 
Chlorpromazine [48], [49], Drugbank, ChEMBL [50] 
Ciprofloxacin [42], [51] [52] 
Clozapine [48], [49], [53] [54] 
Compound A  Internal data Internal data 
Compound B Internal data Internal data 
Compound C Internal data Internal data 
Compound X [3] [3] 
Digoxin [55] [56] 
Diltiazem [48], [49], [53] [57] 
Ibuprofen [48], [49], [53] [58] 
Levothyroxine [41], ChEMBL [41] 
Metoprolol [59] [59] 
Midazolam [19] [60], [61] 
Nifedipine [62], [63] [64], [65] 
NVS732 [43] [43] 
Paracetamol [66] [66] 
PF-02413873 [67] [67] 
Pracinostat [68] [68] 
Repaglinide [69], [70] [71] 
TPN729MA [72] [72] 
Sotalol [66] [66] 
UK-453,061 [73] [73] 
Verapamil [48], [49], [53] [74] 
Note that, as a general rule, all the PBPK model compound-related parameter values were computed, 
starting from the compound properties reported in Table 2, by applying the mathematical relationships 
reported in the previous sections and in the Supplementary Material. However, if the in vitro intrinsic 
clearance, required to characterize the hepatic metabolism, was not available, or the in vivo data of the 
plasma clearance CLP was available, the hepatic extraction ratio EH was directly calculated using the in vivo 
data as: 
EH = CLB,nr/QLiver (20) 
where CLB,nr is the non-renal blood clearance obtained as CLP,nr/BP and CLP,nr is the non-renal plasma 
clearance obtained after IV administration. If information about non-renal clearance were not available the 
total plasma clearance CLP was used. 
Moreover, FGUT values in man were fixed to the values reported in the literature [53], if available, or 
calculated using the “QGUT” model where possible; for the other species FGUT was fixed to 1. 
Figure 3 reports, as an example, simulations related to an IV study (drug Paracetamol) and a PO study 
(drug Clozapine). 
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Figure 3. Predicted profiles (blue line) and the experimental data (red circles) in case of an IV infusion of 
Paracetamol (left panel) and a PO administration of Clozapine (right panel) in humans. For Paracetamol no 
adjustments were applied; for Clozapine, even if no IV data were available, the PS coefficient was increased 
to obtain a perfusion-limited kinetics. 
When for the same drug both IV and PO data were available, PO predictions were obtained after having 
adjusted, if needed, model parameters on the IV data, as suggested by Peters in her work [16]. In particular, 
the drug distribution was adjusted multiplying all the partition coefficients for the same factor and tuning 
the PS parameters of the permeability limited tissues. In general, this procedure improved predictions of 
PO administrations. An example of the benefit of tuning the partition coefficients on IV profile is reported 
in Figure 4 for drug Nifedipine.  
 
Figure 4. Comparison between PBPK simulated profiles tuning partition coefficients on IV data (blue line) and 
without tuning them (red line) for the drug Nifedipine. Experimental data are black circles. Left panel is 
related to an IV administration and right panel to PO administration. 
The choice of adjusting the distribution on the in vivo data and of using the in vivo clearance to calculate 
the hepatic extraction ratio wants to simulate the incremental model building process mentioned in the 
introduction, in which the knowledge is progressively added as soon as it is made available during the 
development process to refine the model. For highly lipophilic compounds, such as Clozapine and 
Amitriptyline, PS values were adjusted directly on PO simulations, when the IV data were not available, 
increasing PS values with the same factor2 to reach perfusion limited kinetics. This improved predictions 
                                                     
 
2
 Amitryptiline, log P 4.85, PS correction coefficient 10
4
; Chlorpromazione, log P 5.18, correction coefficient 10
4
; Clozapine, 
log P 3.42, correction coefficient 10
3
; Verapamil, log P 4.05, correction coefficient 10
4
. 
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when compared with real data. 
Simulations were evaluated by considering the main pharmacokinetic parameters, i.e. area under the 
curve (AUC) of the plasma concentration-time profile, its maximum concentration values (Cmax) and the 
time to reach the maximum concentration (Tmax). In particular, AUC was considered for both the IV and PO 
experiments, whereas Cmax and Tmax were considered only for PO administrations and for IV infusions. The 
comparison between values computed on simulated and experimental profiles was made in terms of fold 
error: 
Fe = Ppred/Pobs (21) 
where Ppred is the PK parameter computed on the PBPK model predicted data and Pobs refers to those 
obtained from the experimental data. 
In Figure 5, the comparison between the predicted and observed parameters is shown. 
 
 
Figure 5. Comparison of the predicted and observed PK parameters, AUC in the upper left panel, Cmax in the 
upper right panel, Tmax in the panel below. The black lines represent the two-fold line deviation. 
It can be observed that for a large number of cases the predicted PK parameters are inside the two-fold 
limit. 
Fold error values are reported in the Supplementary Material (Model evaluation results section) for all 
the compounds. As a metric of the overall performance the average fold error was calculated [16] for the 






  (22) 
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The average fold error for the AUC is 0.98, for the Cmax 1.1 and for the Tmax 1.37. The model showed good 
prediction performances since the Afe is for all the parameters under the two-fold limit. However, it should 
be considered that the use of the in vivo clearance data (where available) contributed to improve the 
predictive performances of the model, since is known that in vitro clearance measurements are often under 
predictive of the in vivo clearance [16]. Moreover, it should be noted that the PBPK model here presented 
does not consider possible kinetics caused by the action of specific enzymes and transporters that could 
play an important role in some cases. For example, they could allow the model to capture non-linearities in 
the PK due to some saturation effects. This behaviour can occur for mechanisms associated with 
absorption, first pass metabolism, binding, excretion and biotransformation; an example is the partial 
saturation of presystemic metabolism, one of the most important sources of non-linearity [75]. The 
modelling of specific kinetics could also be necessary to improve the model prediction capabilities in case of 
complex BCS class IV drugs, characterized by low solubility and low permeability for which the action of 
absorptive and efflux transporters could play an important role in their disposition [76]. 
Conclusions 
This paper shows, through a specific example, how it is possible to create in-house PBPK modelling 
tools, starting from the literature information and using some in vitro drug-specific properties that are 
typically routinely collected during the drug development process. Some references regarding how to 
model the basic ADME processes and where the main physiological parameter values can be found are also 
provided. For helping the reader, all the parameter values for rat, dog and man or the relationships to 
obtain these values are summarized in the Supplementary Material.  
The developed PBPK model was evaluated in three different species on 25 compounds, intravenously 
and/or orally administered. It shows good performances in predicting the main PK parameters. The use of 
the in vivo IV data, when available, for the adjustment of the distribution parameters as well as for the 
prediction of the hepatic clearance proves to be a useful strategy to improve predictions of the plasma 
concentration-time profiles following other routes of administration.  
This study demonstrates that it is possible to create simplified in-house PBPK tools, which can be the 
basis for the subsequent study of specific ADME mechanisms associated with special routes of 
administration. For example, our aim is to inform and support the drug development process by using the 
proposed PBPK model, extended with a pulmonary model we are working on, to study the PK of inhaled 
drugs. It is well known that a part of the inhaled drug can be swallowed immediately after inhalation or 
after the deposition for mucociliary clearance action. Hence, in this context, the possibility to correctly 
predict the gastrointestinal absorption can be useful to monitor the systemic exposure of inhaled drugs.  
In this view, the evaluation of a PBPK model platform is an important and critical step of the model 
development, as also mentioned in both the EMA and FDA guidance [11,12]. In particular, the EMA 
guidance affirms that if a PBPK model is intended to support a regulatory decision, it has to be qualified for 
the intended use. Therefore, the evaluation of the model predictive performances and the level of 
qualification depend on the impact that the modelling exercise has on the decision making and on the 
patient’s risk associated to wrong regulatory decisions based on modelling predictions. Even if most of the 
regulatory submissions including PBPK models deals with the use of commercially available specialized (and 
validated) software tools [11], the use of in-house built platform is not discouraged by the regulatory 
agencies. In fact, FDA guideline does not prescribe the use of particular software for PBPK modelling and 
the EMA guideline applies also to in-house built PBPK platforms. However, it is clearly reported that if an in-
house built platform is used for high regulatory impact simulations (e.g., as an alternative to clinical studies) 
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the applicant is strongly encouraged to seek the Committee for Medicinal Product for Human Use (CHMP) 
Scientific Advice for further guidance [11]. 
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